Explore tweets tagged as #DynamXBioadaptor
For Polish physicians: Register today for the case-based discussion on the treatment of Coronary Artery Disease with #DynamXBioadaptor. We will be joined by the panel of experts. @HawranekMichal will be sharing the biggest challenges in PCI today and how the novel mechanism of
0
0
3
🌎 Enter #XCASE Global Case Comp now! Show your brilliance in Vessel Restoration on Wondr Medical. Top 3 cases shine at Elixir Symposium EuroPCR2024. Don't miss this cardiology spotlight. #DynamXBioadaptor #EuroPCR2024 #XCASE #DynamXBioadaptor. PMN 1501 Rev B
0
0
2
Join #XCASE Global Case Competition by Elixir Medical! Share your DynamX Bioadaptor case with a brief description and relevant imaging to participate. The top 3 cases get a chance to present at Elixir Symposium EuroPCR2024. #XCASE #DynamXBioadaptor #EuroPCR2024. PMN 1500 Rev B
0
1
0
📚 Recent findings from the INFINITY-SWEDEHEART RCT revealed at #ESC2024 show that the #DynamXBioadaptor meets primary endpoint and significantly reduced adverse events compared to DES at six months. 💡 Watch the full summary by Dr Erlinge to see how this could impact CAD
0
0
0
Packed house at both the #EuroPCR late-breaking session with Shigeru Saito, M.D., and our case-in-point symposium led by Antonio Colombo, M.D., on Wednesday! Learn more about our new data: #CardioTwitter #Cardiology . *CE marked. Not approved in the U.S.
0
3
6
New 12-month DynamX Bioadaptor clinical data show statistically significant effectiveness compared to DES in the BIOADAPTOR RCT trial. View the full results: #CardioTwitter #EuroPCR. *CE marked. Not approved in the U.S.
0
6
11
Stop by Elixir's booth N4 at #EuroPCR to discover the future of vascular intervention. DynamX® Bioadaptor showed statistically significant effectiveness (non-inferiority) to leading DES at 12-months: #CardioTwitter . *CE marked. Not approved in the U.S.
0
1
4
DYK? Over 5.5 million PCI procedures were performed globally in 2022. Elixir is innovating for the future of vascular intervention with the DynamX® bioadaptor. Learn more here: . #CardioTwitter #Innovation . *CE marked. Not approved in the U.S.
0
2
1
Check out this piece from Elixir CEO Motasim Sirhan on the need for a decisive win in treating coronary artery.disease and the effort behind developing a completely new category of coronary implant. Learn more about DynamX Bioadaptor here: PMNÂ 1563 Rev A.
0
2
2